調査レポートカテゴリー： MarketsandMarkets, 世界

Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024

血液腫瘍検査の世界市場予測（～2024年）

◆タイトル：Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024
◆商品コード：MD-7180
◆調査・発行会社：MarketsandMarkets
◆発行日：2019年6月24日
◆ページ数：117
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,650 ⇒換算￥0見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥0見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥0見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

 【レポートの概要】

当調査レポートでは、血液腫瘍検査の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品＆サービス別（アッセイキット、サービス）分析、がん別（白血病（急性リンパ芽球性、急性骨髄性）、非ホジキンリンパ腫）分析、技術別（PCR、NGS、IHC）分析、エンドユーザー別（臨床研究所、病院）分析、血液腫瘍検査の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。MarketsandMarkets社は、血液腫瘍検査のの世界市場規模が2019年20億ドルから2024年40億ドルまで年平均14.8％成長すると予測しています。

“Hemato oncology testing market to register a CAGR of 14.8% from 2019 to 2024”
The hemato oncology testing market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8% during the forecast period. Growth in this market is mainly driven by the rising incidences & prevalence of leukemia, increasing collaborations for developing new assay kits, and the growing focus on personalized medicine.

“Services accounted for the larger share of the hemato oncology testing market in 2018”

Based on product & service, the market is segmented into assay kits and services. In 2018, the services segment accounted for a larger share of this market majorly due to the high prevalence of leukemia & lymphoma. The market is set to grow on account of increasing collaborations between hemato oncology testing product manufacturers and pharmaceutical companies.

“Leukemia accounted for the largest share of the hemato oncology testing market in 2018”

Based on cancer type, the hemato oncology testing market has been segmented into three types— leukemia, lymphoma, and other cancers. Leukemia accounted for the largest share in 2018 and is anticipated to witness the highest growth rate during the forecast period due to the need for continuous monitoring of leukemia patients. In addition, increasing awareness about checking the status of minimal residual disease (MRD) in leukemia patients is another factor supporting market growth.

“North America dominates the hemato oncology testing market”

North America, which includes the US and Canada, accounted for the largest share of the hemato oncology testing in 2018. The large share of this market segment can be attributed to the availability of reimbursement for hemato oncology testing products, increasing awareness regarding advanced treatment theories, and the strong presence of industry players in the region.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1: 70% , Tier 2: 20%, and Tier 3: 10%
• By Designation: C-level: 30%, Director-level: 20%, and Others: 50%
• By Region: North America: 35%, Europe: 24%, Asia: 25%, and the RoW: 16%

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).

Research Coverage
This report studies the hemato oncology testing market based on product & service, cancer type, technology, end user, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro-markets with respect to their growth trends, prospects, and contributions to the total hemato oncology testing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the hemato oncology testing offered by the top 12 players in the market. The report analyzes the hemato oncology testing market by product and region

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various hemato oncology testing across key geographic regions

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the hemato oncology testing market

• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the hemato oncology testing market

【レポートの目次】

1 Introduction (Page No. – 13)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders
2 Research Methodology (Page No. – 16)
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study
3 Executive Summary (Page No. – 23)
4 Premium Insights (Page No. – 27)
4.1 Hemato-Oncology Testing: Market Overview
4.2 North America: Market, By Product and Service (2018)
4.3 Geographical Snapshot of the Hemato Oncology Testing Market
5 Market Overview (Page No. – 30)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Incidence of Hematologic Cancer
5.2.1.2 Increasing Collaborations
5.2.1.3 Increasing Conferences on Personalized Medicine
5.2.2 Opportunities
5.2.2.1 Drug Diagnostics Co-Development
5.2.2.2 Emerging Markets
5.2.3 Restraints
5.2.3.1 Uncertain Reimbursement Scenario in Different Regions
5.2.3.2 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
5.2.4 Challenges
5.2.4.1 Intellectual Property Rights Protection Issues
6 Hemato Oncology Testing Market, By Product & Service (Page No. – 37)
6.1 Introduction
6.2 Services
6.2.1 Rising Incidence of Hematologic Cancer to Increase the Demand for Hemato-Oncology Services
6.3 Assay Kits
6.3.1 Growing Focus on the Development of Advanced Assay Kits to Drive the Growth of This Market Segment
7 Hemato Oncology Testing Market, By Cancer Type (Page No. – 42)
7.1 Introduction
7.2 Leukemia
7.2.1 Acute Myeloid Leukemia
7.2.1.1 Aml is the Most Common Acute Leukemia Affecting Adults
7.2.2 Acute Lymphocytic Leukemia
7.2.2.1 North America Accounted for the Largest Share of the All Segment
7.2.3 Other Leukemias
7.3 Lymphoma
7.3.1 Non-Hodgkin Lymphoma
7.3.1.1 Non-Hodgkin Lymphoma Holds the Largest Share of the Market for Lymphoma
7.3.2 Hodgkin Lymphoma
7.3.2.1 APAC Market for Hodgkin Lymphoma Will Grow at the Highest Rate
7.4 Other Cancers
8 Hemato Oncology Testing Market, By Technology (Page No. – 50)
8.1 Introduction
8.2 PCR
8.2.1 PCR Accounted for the Largest Share of the Market in 2018
8.3 IHC
8.3.1 IHC Accounted for the Second-Largest Share of the Market
8.4 NGS
8.4.1 NGS is Expected to Register the Highest Growth During the Forecast Period
8.5 Cytogenetics
8.5.1 North America Accounted for the Largest Share of the Cytogenetics Market
8.6 Other Technologies
9 Hemato Oncology Testing Market, By End User (Page No. – 56)
9.1 Introduction
9.2 Clinical Laboratories
9.2.1 Presence of Robust Infrastructure is the Major Driving Factor for This Segment
9.3 Hospitals
9.3.1 Hospitals Accounted for the Second-Largest Share of the Market, By End User
9.4 Academic & Research Institutes
9.4.1 APAC Market for Academic & Research Institutes Will Grow at the Highest Rate
9.5 Other End Users
10 Hemato Oncology Testing Market, By Region (Page No. – 62)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 The US Dominates the North American Market
10.2.2 Canada
10.2.2.1 Initiatives Undertaken By Healthcare Authorities in the Country to Ensure the Delivery of Better Public Healthcare to Support the Growth of the Market in Canada
10.3 Europe
10.3.1 Rising Focus on Biomarker Development in EU Countries to Support Market Growth
10.4 Asia Pacific
10.4.1 Asia Pacific Market to Witness the Highest Growth During the Forecast Period
10.5 Rest of the World
11 Competitive Landscape (Page No. – 84)
11.1 Overview
11.2 Market Ranking Analysis, 2017
11.3 Key Strategies
11.3.1 Product Launches & Approvals, 2016–2019
11.3.2 Expansions, 2016–2019
11.3.3 Partnerships and Collaborations, 2016–2019
11.3.4 Acquisitions, 2016–2019
12 Company Profiles (Page No. – 88)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 F. Hoffman-La Roche Ltd.
12.2 Abbott Laboratories
12.3 Qiagen N.V.
12.4 Thermo Fisher Scientific, Inc.
12.5 Illumina, Inc.
12.6 Bio-Rad Laboratories, Inc.
12.7 Molecularmd (Subsidiary of Icon PLC)
12.8 Archerdx, Inc.
12.9 Arup Laboratories Inc.
12.10 Asuragen, Inc.
12.11 Invivoscribe, Inc.
12.12 Adaptive Biotechnologies.
*Details on Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. – 109)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Available Customizations
13.5 Related Reports
13.6 Author Details

List of Tables (77 Tables)
Table 1 Hematologic Cancer Incidence, By Type, 2018–2040
Table 2 Geriatric Population, By Region, 2015 vs 2030
Table 3 Health Expenditure Per Capita, By Country, 2009 vs 2016
Table 4 Incidence of Hematologic Cancers, By Country, 2018 vs 2030
Table 5 Reimbursement Scenario for Hemato-Oncology Testing Products Across Regions
Table 6 Market, By Product & Service, 2017–2024 (USD Million)
Table 7 Hemato-Oncology Testing Services Market, By Region, 2017–2024 (USD Million)
Table 8 Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 9 Hemato-Oncology Testing Assay Kits Market, By Region, 2017–2024 (USD Million)
Table 10 Market, By Cancer Type, 2017–2024 (USD Million)
Table 11 Hemato Oncology Testing Market for Leukemia, By Region, 2017–2024 (USD Million)
Table 12 Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 13 Market for Acute Myeloid Leukemia, By Region, 2017–2024 (USD Million)
Table 14 Market for Acute Lymphocytic Leukemia, By Region, 2017–2024 (USD Million)
Table 15 Market for Other Leukemias, By Region, 2017–2024 (USD Million)
Table 16 Market for Lymphoma, By Region, 2017–2024 (USD Million)
Table 17 Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 18 Market for Non-Hodgkin Lymphoma, By Region, 2017–2024 (USD Million)
Table 19 Hemato Oncology Testing Market for Hodgkin Lymphoma, By Region, 2017–2024 (USD Million)
Table 20 Market for Other Cancers, By Region, 2017–2024 (USD Million)
Table 21 Market, By Technology, 2017–2024 (USD Million)
Table 22 Market for PCR, By Region, 2017–2024 (USD Million)
Table 23 Market for IHC, By Region, 2017–2024 (USD Million)
Table 24 Market for NGS, By Region, 2017–2024 (USD Million)
Table 25 Market for Cytogenetics, By Region, 2017–2024 (USD Million)
Table 26 Hemato Oncology Testing Market for Other Technologies, By Region, 2017–2024 (USD Million)
Table 27 Market, By End User, 2017–2024 (USD Million)
Table 28 Market for Reference Laboratories, By Region, 2017–2024 (USD Million)
Table 29 Market for Hospitals, By Region, 2017–2024 (USD Million)
Table 30 Market for Academic & Research Institutes, By Region, 2017–2024 (USD Million)
Table 31 Market for Other End Users, By Region, 2017–2024 (USD Million)
Table 32 Market, By Region, 2017–2024 (USD Million)
Table 33 North America: Market, By Country, 2017–2024 (USD Million)
Table 34 North America: Market, By Product & Service, 2017–2024 (USD Million)
Table 35 North America: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 36 North America: Market, By Cancer Type, 2017–2024 (USD Million)
Table 37 North America: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 38 North America: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 39 North America: Market, By Technology, 2017–2024 (USD Million)
Table 40 North America: Hemato Oncology Testing Market, By End User, 2017–2024 (USD Million)
Table 41 US: Leukemia at A Glance
Table 42 US: Market, By Product & Service, 2017–2024 (USD Million)
Table 43 US: Market, By Cancer Type, 2017–2024 (USD Million)
Table 44 US: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 45 US: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 46 US: Market, By Technology, 2017–2024 (USD Million)
Table 47 US: Market, By End User, 2017–2024 (USD Million)
Table 48 Canada: Hemato Oncology Testing Market, By Product & Service, 2017–2024 (USD Million)
Table 49 Canada: Market, By Cancer Type, 2017–2024 (USD Million)
Table 50 Canada: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 51 Canada: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 52 Canada: Market, By Technology, 2017–2024 (USD Million)
Table 53 Canada: Market, By End User, 2017–2024 (USD Million)
Table 54 Incidence of Leukemia, By Country, 2018–2035
Table 55 Europe: Market, By Product & Service, 2017–2024 (USD Million)
Table 56 Europe: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 57 Europe: Market, By Cancer Type, 2017–2024 (USD Million)
Table 58 Europe: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 59 Europe: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 60 Europe: Market, By Technology, 2017–2024 (USD Million)
Table 61 Europe: Market, By End User, 2017–2024 (USD Million)
Table 62 Geriatric Population, By Country, 2015 vs 2030
Table 63 Asia Pacific: Market, By Product & Service, 2017–2024 (USD Million)
Table 64 Asia Pacific: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 65 Asia Pacific: Market, By Cancer Type, 2017–2024 (USD Million)
Table 66 Asia Pacific: Hemato Oncology Testing Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 67 Asia Pacific: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 68 Asia Pacific: Market, By Technology, 2017–2024 (USD Million)
Table 69 Asia Pacific: Market, By End User, 2017–2024 (USD Million)
Table 70 RoW: Market, By Product & Service, 2017–2024 (USD Million)
Table 71 RoW: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 72 RoW: Market, By Cancer Type, 2017–2024 (USD Million)
Table 73 RoW: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 74 RoW: Hematon Oncology Testing Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 75 RoW: Market, By Technology, 2017–2024 (USD Million)
Table 76 RoW: Market, By End User, 2017–2024 (USD Million)
Table 77 Ranking of Companies in the Market, 2018

List of Figures (29 Figures)
Figure 1 Hemato Oncology Testing Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market: Bottom-Up Approach
Figure 5 Market: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Hemato Oncology Testing Market, By Product and Service, 2019 vs 2024 (USD Million)
Figure 8 Market, By Cancer Type, 2019 vs 2024 (USD Million)
Figure 9 Market, By Technology, 2019 vs 2024 (USD Million)
Figure 10 Market, By End User, 2019 vs 2024 (USD Million)
Figure 11 Market, By Region, 2019 vs 2024 (USD Million)
Figure 12 Increasing Incidence of Hematology Cancer to Drive Market Growth
Figure 13 Services to Dominate the North American Market in 2018
Figure 14 North America Accounted for the Largest Market Share in 2018
Figure 15 Hemato Oncology Testing Market: Drivers, Restraints, Opportunities, & Challenges
Figure 16 Market, By Product & Service (2019 vs 2024)
Figure 17 Market, By Cancer Type (2019 vs 2024)
Figure 18 Market, By Technology (2019 vs 2024)
Figure 19 Market, By End User (2019 vs 2024)
Figure 20 Market, By Region (2019 vs 2024)
Figure 21 North America: Hemato Oncology Testing Market Snapshot
Figure 22 Key Developments in the Market From 2016 to 2018
Figure 23 Roche Diagnostic: Company Snapshot (2018)
Figure 24 Abbott Laboratories: Company Snapshot (2018)
Figure 25 Qiagen N.V.: Company Snapshot (2018)
Figure 26 Thermo Fisher Scientific: Company Snapshot (2018)
Figure 27 Illumina, Inc.: Company Snapshot (2018)
Figure 28 Bio-Rad Laboratories, Inc.: Company Snapshot (2018)
Figure 29 Icon PLC: Company Snapshot (2018)

★調査レポート[血液腫瘍検査の世界市場予測（～2024年）] ( Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024 / MD-7180) 販売に関する免責事項
[血液腫瘍検査の世界市場予測（～2024年）] ( Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024 / MD-7180) についてEメールでお問い合わせ

※関連データはありません。


◆H&Iグローバルリサーチ株式会社のお客様（例）◆